静脉注射唑来膦酸后组织蛋白酶K在治疗监测中的作用
Cathepsin K in treatment monitoring following intravenous zoledronic acid.
作者信息
Jahn Oliver, Wex Thomas, Klose Silke, Kropf Siegfried, Adolf Daniela, Piatek Stefan
机构信息
Department of Trauma Surgery, Otto von Guericke University, D-39120 Magdeburg, Germany.
Department of Gastroenterology, Hepatology and Infectious Diseases, Otto von Guericke University, D-39120 Magdeburg, Germany ; Medical Laboratory for Clinical Chemistry, Microbiology and Infectious Diseases, Department Molecular Genetics, Otto von Guericke University, D-39124 Magdeburg, Germany.
出版信息
Biomed Rep. 2014 Nov;2(6):915-917. doi: 10.3892/br.2014.360. Epub 2014 Sep 10.
Cathepsin K (CatK) is mainly expressed by osteoclasts and plays an important role in bone resorption. As CatK is expressed and secreted by osteoclasts during active bone resorption, it may be a useful and specific biochemical marker of osteoclastic activity. Therefore, CatK serum levels were studied for monitoring the treatment of females with postmenopausal osteoporosis by zoledronic acid. The serum CatK levels were determined in nine postmenopausal females before and after 3, 6 and 12 months of treatment. The levels were significantly reduced after 3 and 6 months (P<0.05), whereas they returned to baseline after 1 year. Taken together, the serum level of CatK may be suitable for monitoring anti-osteoporotic therapy in association with treatment response.
组织蛋白酶K（CatK）主要由破骨细胞表达，在骨吸收中起重要作用。由于CatK在活跃的骨吸收过程中由破骨细胞表达和分泌，它可能是破骨细胞活性的一个有用且特异的生化标志物。因此，研究了CatK血清水平以监测唑来膦酸治疗绝经后骨质疏松症女性的情况。测定了9名绝经后女性在治疗前以及治疗3、6和12个月后的血清CatK水平。3个月和6个月后水平显著降低（P<0.05），而1年后恢复到基线水平。综上所述，CatK血清水平可能适合与治疗反应相关联地监测抗骨质疏松治疗。
Zotero 插件